Drug Trial Radar · NCT00134056
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Last checked: Nov 20, 2026Latest source record: Oct 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,038
Actual
Start
Aug 2006
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 24, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether docetaxel, prednisone, and atrasentan are more effective than docetaxel and prednisone in treating prostate cancer. PURPOSE: This randomized phase III trial is studying docetaxel, prednisone, and atrasentan to see how well they work compared to docetaxel and prednisone in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy.
Conditions
- Metastatic Cancer
- Prostate Cancer
Interventions
atrasentan hydrochlorideDrug
Given orally
docetaxelDrug
Docetaxel given IV and prednisone given orally
prednisoneDrug
Docetaxel given IV and prednisone given orally
placeboOther
Given orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone Refractory Prostate Cancer.Time frame: Up to 7 years after study opens
- Compare Progression-free Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone Refractory Prostate Cancer.Time frame: Up to 7 years after study opens
Locations
554 sites in 1 country. Site status is shown where the registry gives one.
Providence Cancer Center at Providence Hospital
Mobile, Alabama
Alaska Regional Hospital Cancer Center
Anchorage, Alaska
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska
Mayo Clinic Scottsdale
Scottsdale, Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas
East Bay Radiation Oncology Center
Castro Valley, California
Eden Medical Center
Castro Valley, California
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California
Valley Medical Oncology
Fremont, California
Cancer Care Associates
Fresno, California
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California
Rebecca and John Moores UCSD Cancer Center
La Jolla, California
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California
Community Hospital of the Monterey Peninsula Comprehensive Cancer Center
Monterey, California
Camino Medical Group - Treatment Center
Mountain View, California
El Camino Hospital Cancer Center
Mountain View, California
Highland General Hospital
Oakland, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Bay Area Breast Surgeons, Incorporated
Oakland, California
CCOP - Bay Area Tumor Institute
Oakland, California
Larry G Strieff MD Medical Corporation
Oakland, California
Tom K Lee, Incorporated
Oakland, California
Desert Regional Medical Center Comprehensive Cancer Center
Palm Springs, California
Palo Alto Medical Foundation
Palo Alto, California
PCR Oncology
Pismo Beach, California
Valley Care Medical Center
Pleasanton, California
Valley Medical Oncology Consultants - Pleasanton
Pleasanton, California
Lucy Curci Cancer Center at Eisenhower Memorial Hospital and Medical Center
Rancho Mirage, California
University of California Davis Cancer Center
Sacramento, California
Mercy General Hospital
Sacramento, California
Salinas Valley Memorial Hospital
Salinas, California
Doctors Medical Center - San Pablo Campus
San Pablo, California
Tahoe Forest Cancer Center
Truckee, California
Aurora Presbyterian Hospital
Aurora, Colorado
University of Colorado Cancer Center at UC Health Sciences Center
Aurora, Colorado
Boulder Community Hospital
Boulder, Colorado
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado
Showing 40 of 554 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.